Clinical Pathology, University of Bari, Bari, Italy.
Immunopharmacol Immunotoxicol. 2010 Mar;32(1):160-4. doi: 10.1080/08923970902936880.
Galectin-3 is an endogenous lectin that binds glycan epitopes of cell membrane and some extracellular glycoproteins such as integrins and laminin. Galectin-3 is involved in several biological activities including regulation of cellular cycle, modulation of adhesion and tumor progression and metastasis. 90K/Mac-2BP glycoprotein is also a serum galectin-3 ligand. 90K is able to modulate the immune reaction against tumors and viruses and its level increases in sera of several neoplastic diseases. In our study, we have evaluated levels of both glycoproteins in sera of non metastatic colon cancer patients. Interestingly, galectin-3 ranged higher in cancer patients than in controls (p<0.0001), particularly in more differentiated tumors (p<0.04). Moreover, 90K mean values ranged higher in right-side than in left-side colon cancer. In conclusion, serum galectin3 might represent a useful biomarker to evaluate colon cancer transformation and, together with its ligand 90K, could contribute to the characterization of colon cancer.
半乳糖凝集素-3 是一种内源性凝集素,可与细胞膜上的糖基表位和一些细胞外糖蛋白(如整合素和层粘连蛋白)结合。半乳糖凝集素-3 参与了多种生物学活性,包括细胞周期的调节、黏附的调节以及肿瘤的进展和转移。90K/Mac-2BP 糖蛋白也是血清半乳糖凝集素-3 的配体。90K 能够调节针对肿瘤和病毒的免疫反应,其水平在几种肿瘤性疾病的血清中升高。在我们的研究中,我们评估了非转移性结肠癌患者血清中这两种糖蛋白的水平。有趣的是,癌症患者的半乳糖凝集素-3 水平高于对照组(p<0.0001),特别是在分化程度更高的肿瘤中(p<0.04)。此外,右半结肠癌患者的 90K 平均值高于左半结肠癌患者。总之,血清半乳糖凝集素-3 可能是评估结肠癌转化的有用生物标志物,与配体 90K 一起,可能有助于结肠癌的特征描述。